GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Price-to-Tangible-Book

Cascadian Therapeutics (Cascadian Therapeutics) Price-to-Tangible-Book : 5.49 (As of Apr. 25, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Price-to-Tangible-Book?

As of today (2024-04-25), Cascadian Therapeutics's share price is $10.02. Cascadian Therapeutics's Tangible Book per Share of Dec. 2017 for the quarter that ended in Dec. 2017 was $1.83. Hence, Cascadian Therapeutics's Price to Tangible Book Ratio of today is 5.49.

The historical rank and industry rank for Cascadian Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

CASC's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.67
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Cascadian Therapeutics's share price is $10.02. Cascadian Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2017 was $2.16. Hence, Cascadian Therapeutics's P/B Ratio of today is 4.65.


Cascadian Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Cascadian Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Price-to-Tangible-Book Chart

Cascadian Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.79 3.17 4.45 1.69 2.03

Cascadian Therapeutics Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.51 1.51 1.92 2.03

Competitive Comparison of Cascadian Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Cascadian Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Price-to-Tangible-Book falls into.



Cascadian Therapeutics Price-to-Tangible-Book Calculation

Cascadian Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2017 )
=10.02/1.826
=5.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Cascadian Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland officer: CFO & CBO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers director, officer: President and CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson 07-11-2016